How to buy Monopar Therapeutics stock (MNPR)

Monopar Therapeutics is a biotechnology business based in the US. Monopar Therapeutics shares (MNPR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $25.82 – an increase of 1.73% over the previous week. Monopar Therapeutics employs 9 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Monopar Therapeutics stock

Buy Monopar Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Monopar Therapeutics stock price (NASDAQ: MNPR)

Use our graph to track the performance of MNPR stocks over time.

Monopar Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$25.82
52-week range	$1.55 - $38.50
50-day moving average more info button	$16.57
200-day moving average more info button	$6.79
Wall St. target price	$27.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.98

Is it a good time to buy Monopar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Monopar Therapeutics price performance over time

Historical closes compared with the close of $23.79 from 2024-12-19

1 week (2024-12-13)	-6.26%
1 month (2024-11-22)	18.36%
3 months (2024-09-20)	424.01%
6 months (2024-06-21)	3,347.83%

1 year (2023-12-22)	5,877.39%
2 years (2022-12-22)	95.80%
3 years (2021-12-22)	38.31%
5 years (2019-12-20)	135

Monopar Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-53.45%
Return on equity TTM	-102.31%
Profit margin	0%
Book value	$1.88
Market Capitalization more info button	$158 million

TTM: trailing 12 months

Monopar Therapeutics share dividends

We're not expecting Monopar Therapeutics to pay a dividend over the next 12 months.

Have Monopar Therapeutics's shares ever split?

Monopar Therapeutics's shares were split on a 1:5 basis on 12 August 2024 . So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Monopar Therapeutics shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Monopar Therapeutics shares which in turn could have impacted Monopar Therapeutics's share price.

Monopar Therapeutics share price volatility

Over the last 12 months, Monopar Therapeutics's shares have ranged in value from as little as $1.545 up to $38.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Monopar Therapeutics's is 1.104. This would suggest that Monopar Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Monopar Therapeutics overview

Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Frequently asked questions

What percentage of Monopar Therapeutics is owned by insiders or institutions?
Currently 42.938% of Monopar Therapeutics shares are held by insiders and 24.474% by institutions. How many people work for Monopar Therapeutics?
Latest data suggests 9 work at Monopar Therapeutics. When does the fiscal year end for Monopar Therapeutics?
Monopar Therapeutics's fiscal year ends in December. Where is Monopar Therapeutics based?
Monopar Therapeutics's address is: 1000 Skokie Boulevard, Wilmette, IL, United States, 60091 What is Monopar Therapeutics's ISIN number?
Monopar Therapeutics's international securities identification number is: US61023L1089 What is Monopar Therapeutics's CUSIP number?
Monopar Therapeutics's Committee on Uniform Securities Identification Procedures number is: 61023L108